HomePeptides › Humanin

Humanin

HN, MTRNR2

Tier 4 · Preclinical Only
Class
Mitochondrial-derived peptide
Molecular target
Trimeric receptor (CNTFR/WSX-1/gp130); IGFBP-3 binding
Sequence / structure
MAPRGFSCLLLLTSEIDLPVKRRA
Evidence tier
Tier 4 — Preclinical Only
Category
Mitochondrial & Longevity
Emergency card
Signs something is wrong

Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.

What to do now

Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.

When it is an emergency

Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.

Any injection — every time

Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.

This is not permission or instruction to use this compound. It is harm-reduction information for someone who has already decided to, so that a bad reaction is recognised and treated. When in doubt, get help — embarrassment is survivable.

Biology & mechanism

A 24-amino-acid peptide encoded within the mitochondrial 16S rRNA gene, identified through screens for cytoprotective factors in Alzheimer's disease models. It signals through a trimeric cell-surface receptor complex and also binds IGFBP-3, with reported anti-apoptotic effects. Circulating levels decline with age.

What the research actually shows

Preclinical work reports neuroprotective and cytoprotective effects in cellular and rodent models. Human data are observational — associations between levels and ageing or disease — not interventional. No trials establish benefit from administration.

Regulatory status

Not FDA-approved.

Safety signals

No meaningful human safety data. Anti-apoptotic activity warrants theoretical oncological caution.

Clinical trial dosing — what the studies actually used

No human trial has ever established a dose for this compound. Any figure circulating online is extrapolated from animal studies or copied between vendors — it was not validated in people. That absence is the single most important dosing fact on this page.

Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.

We report study doses, not protocols

Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.

References & further reading

Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.

Important notice Forge Bioenergy publishes scientific reference information only. Nothing on this site is medical advice, a therapeutic claim, or a recommendation to use any substance in humans. Many peptides described here are not approved by the FDA for any use, and several are approved only for narrow indications under prescription. We do not publish dosing, administration, or usage protocols. Consult a licensed physician before making any medical decision.